An inspiring journey shared about the power of the PARIS test in battling low-grade serous ovarian cancer. Cancer can plunge individuals into uncertainty and fear, but functional tumor testing like the PARIS® Test can offer a guiding light. This revolutionary approach not only sheds light on unique cancer characteristics but also becomes a critical tool in the fight against this rare adversary.
Diagnostics and drug discovery work hand in hand
SEngine Precision Medicine Partners with Vincere Cancer Center to Increase Access for First Responders to Get Personalized Cancer Treatments via the PARIS® Test
Prospective joint venture will accelerate precision medicine in Europe by harnessing innovations in high-throughput drug testing and 3D tumor cell culture.
Strong Predictive Value of Organoid-Based PARIS® Test to Identify Personalized Treatments in Advanced Cancers Presented at 2021 ASCO Annual Meeting
SEngine Precision Medicine to Present Pan Cancer Data on Predictive Value of PARIS® Test at 2021 ASCO Annual Meeting
SEngine Presents Data at 2021 AACR Annual Meeting Demonstrating Clinical Utility and Predictive Value of PARIS® Test in Ovarian Cancer
Predictive Value of PARIS® Test in Ovarian Cancer Patients at 2021 AACR Annual Conference
Precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived tumor organoids
SEngine to present Predictive Value of PARIS® Test in Breast Cancer Patients at 2020 San Antonio Breast Cancer Symposium
Novel Drug Combinations for PARP Inhibitor Resistant Ovarian Cancer in Study Published in EBioMedicine
Clinical Utility demonstrated in Metastatic Colorectal Cancer Study Published in AACR’s Clinical Cancer Research
Results of the PARIS Test showed a 92% correlation between organoid drug sensitivity and patient response to previous treatments
PARIS® Test for Oncology Drugs Based on Retrospective Analysis presented at 2020 ASCO Annual Meeting
Predictive Value of PARIS® Test, an Organoid-based Drug Response Assay, for Cholangiocarcinoma Patients presented at 2020 AACR Virtual Meeting Session II
SEngine Precision Medicine Announces Experienced Technology Executive Tom Neary as Chief Financial Officer
